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Abstract
This study was conducted to assess the effects of long-term Se administration on the regression and metabolic status of patients with cervical
intraepithelial neoplasia grade 1 (CIN1). This randomised, double-blind, placebo-controlled trial was carried out among fifty-eight women
diagnosed with CIN1. To diagnose CIN1, we used specific diagnostic procedures of biopsy, pathological diagnosis and colposcopy. Patients were
randomly assigned to two groups to receive 200 μg Se supplements as Se yeast (n 28) or placebo (n 28) daily for 6 months. After 6 months of
taking Se supplements, a greater percentage of women in the Se group had regressed CIN1 (88·0 v. 56·0 %; P= 0·01) compared with those in the
placebo group. Long-term Se supplementation, compared with the placebo, resulted in significant decreases in fasting plasma glucose levels
(−0·37 (SD 0·32) v. +0·07 (SD 0·63) mmol/l; P= 0·002), serum insulin levels (−28·8 (SD 31·2) v. +13·2 (SD 40·2) pmol/l; P< 0·001), homeostatic model
assessment of insulin resistance values (−1·3 (SE 1·3) v. +0·5 (SE 1·4); P< 0·001) and a significant elevation in quantitative insulin sensitivity check
index (+0·03 (SD 0·03) v. −0·01 (SD 0·01); P< 0·001). In addition, patients who received Se supplements had significantly decreased serum TAG
(−0·14 (SD 0·55) v. +0·15 (SD 0·38)mmol/l; P= 0·02) and increased HDL-cholesterol levels (+0·13 (SD 0·21) v. −0·01 (SD 0·15)mmol/l; P= 0·003).
In addition, compared with the placebo group, there were significant rises in plasma total antioxidant capacity (+186·1 (SD 274·6) v. +42·8
(SD 180·4)mmol/l; P= 0·02) and GSH levels (+65·0 (SD 359·8) v. −294·2 (SD 581·8) μmol/l; P= 0·007) and a significant decrease in malondialdehyde
levels (−1·5 (SD 2·1) v. +0·1 (SD 1·4) μmol/l; P= 0·001) among those who took Se supplements. Overall, taking Se supplements among patients with
CIN1 led to its regression and had beneficial effects on their metabolic profiles.
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Cervical intraepithelial neoplasia (CIN) is a potentially
premalignant transformation, which may remain harmlessly or
get eliminated(1). The likelihood of regression of cervical
intraepithelial neoplasia grade 1 (CIN1) is approximately 60%(2),
and, if not treated, the risk of progression to invasive cervical
carcinoma is about 30–50%(3). The main risk factors for
CIN1 are sexually transmitted diseases and productive human
papillomavirus (HPV) infection(4). In addition, several studies
have shown that increased inflammatory cytokines and bio-
markers of oxidative stress would result in higher cervicovaginal
HPV concentrations(5,6), which in turn cause cells to become
more vulnerable for the development of cervical cancer(6).
Recently, dietary supplementation of antioxidants has gained
notable interest for the treatment of CIN. Se is an essential trace
element, which plays a key role in various major metabolic
pathways and protects the body from the poisonous effects of
heavy metals(7). An inverse relationship between serum Se levels
and CIN or cervical cancer has been reported(1), and the tissue
concentrations of Se are significantly lower in cervical cancer
tissues compared with paired non-lesion tissues(8). However,
another study did not observe any association between serum
Se levels and invasive cervical cancer at the typical serum
Se levels(9). We have previously reported beneficial effects of Se
supplementation on metabolic profiles, biomarkers of
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inflammation and oxidative stress among women with polycystic
ovary syndrome (PCOS) and gestational diabetes (GDM)(10,11).
Se intake may reduce the risk of cancer through an increased
expression of selenoproteins, protection against oxidative DNA
damage and/or enhanced DNA repair processes(7). These
mechanisms might suggest the importance of Se supplementa-
tion in the process of malignant transformation and proliferation
in cervical carcinogenesis. To the best of our knowledge, no
study is available investigating the effects of Se administration
on regression, markers of insulin metabolism, lipid concentra-
tions, biomarkers of inflammation and oxidative stress in
patients with CIN1. The present study was, therefore, carried
out to evaluate the effects of Se supplementation on regression
and metabolic status in women with CIN1.
Methods
Participants
The present study was a randomised, double-blind clinical trial
in which fifty-eight patients aged between 18 and 55 years
with CIN1 diagnosed by colposcopy, biopsy and pathological
procedures were included(12). Patients attended the Oncology
Clinic at the Arak University of Medical Sciences (AUMS), Iran,
during August 2014 to February 2015. Patients who had an
abnormal Pap smear test, abnormal cervical cytology, abnormal
cervical appearance, postcoital bleeding, intermenstrual bleeding
and chronic vaginal discharge were invited and asked to undergo
colposcopy. The exclusion criteria were as follows: women who
had a history of cervical cancer or other cancers of the lower
genital tract, a history of hysterectomy or destructive therapy
of the cervix and pregnant women. The present study was con-
ducted according to the guidelines laid down in the Declaration
of Helsinki. Written informed consent was obtained from all the
participants. The present study was approved by the ethics
committee of AUMS and has been recorded in the Iranian Registry
of Clinical Trial (http://www.irct.ir: IRCT201412215623N32).
Study design
At the beginning of the study and after stratification of the parti-
cipants based on their baseline BMI (<30 and ≥30 kg/m2) and
age (<35 and ≥35 years), patients were randomly allocated to
take 200 μg Se supplements as Se yeast (n 28) or placebo
(n 28) per d, using blocked randomisation method by a trained
midwife at the maternity clinic. Se supplements and placebos
were provided by Nature Made Co. and Barij Essence Co.,
respectively. The intervention was carried out for 6 months. The
appearance of the placebo tablets (starch), including colour,
shape, size and packaging, were identical to the Se tablets.
Women were advised not to change their diet and physical
activity during the study period. Compliance to the consumption
of Se supplements and placebos was evaluated by asking women
to bring the medication containers and by sending a short mes-
sage to the patients’ cell phones as a reminder. All the patients
completed three dietary records and three physical activity
records (1 weekend day and 2 weekdays) at month 2, 4 and 6 of
the intervention. Nutritionist 4 software (First Databank) was used
to determine nutrient intakes based on dietary records.
Assessment of variables
Weight and height (Seca) were quantified at the beginning of
the study and after 6 months of the intervention in a fasting state
without shoes and with minimal clothing by a trained midwife.
BMI was determined using the height and weight measure-
ments (weight (kg)/height2 (m2)). At the beginning of the study
and at the end, blood samples (10 ml) were collected early
morning after an overnight fast. Blood samples were collected
according to a standard protocol and were immediately
centrifuged (Hettich). Subsequently, the samples were stored at
−80°C until analysis at the AUMS reference laboratory.
Primary outcomes
The primary outcome was CIN1, which was determined through
colposcopy, cervical biopsy and pathological diagnosis at
baseline and 6 months after the intervention. At baseline, in
patients who had an abnormal Pap smear test, abnormal cervical
cytology, abnormal cervical appearance, postcoital bleeding,
intermenstrual bleeding or chronic vaginal discharge, a colpo-
scopy was carried out to diagnose the location and extent of CIN.
Colposcopy (Siemens Co.) was carried out with the woman lying
on her back, with her legs in stirrups and with the buttocks on the
lower edge of the table (a position known as the dorsal lithotomy
position). A speculum was placed in the vagina after the vulva
was examined for any suspicious lesions. Areas of the cervix that
turned dense white after the application of acetic acid or had an
abnormal vascular pattern (e.g. mosaicism and punctuation) were
considered for a biopsy. Specimens were embedded in formalin
solution and then sent for pathological diagnosis. All these
procedures were repeated at the end of the study.
Secondary outcomes
The secondary outcomes were as follows: markers of insulin
metabolism, lipid profiles, biomarkers of inflammation and
oxidative stress. To quantify fasting plasma glucose (FPG),
serum TAG, and VLDL, total, LDL and HDL-cholesterol
concentrations, we used commercially available kits (Pars
Azmun). All inter- and intra-assay CV for FPG and lipid
concentrations were <5 %. Serum insulin was measured using
an ELISA kit (Monobind). The homeostatic model assessment of
insulin resistance (HOMA-IR), homeostatic model assessment of
β-cell function (HOMA-B) and the quantitative insulin sensitivity
check index (QUICKI) were determined according to suggested
formulae(13). Serum high-sensitivity C-reactive protein (hs-CRP)
was determined using a commercial ELISA kit (LDN). Plasma
nitric oxide (NO) was determined by the Giess method(14), total
antioxidant capacity (TAC) was determined using the ferric
reducing antioxidant power (FRAP) method developed by
Benzie & Strain(15), total GSH was determined by the method
of Beutler & Gelbart(16) and malondialdehyde (MDA) levels
were determined using the thiobarbituric acid reactive
substance method(17).
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Statistical methods
Normality of variables was evaluated by visual inspection of
histograms. Log transformation was applied before statistical
analyses, where appropriate. The analyses were performed for all
randomised subjects according to the intention-to-treat (ITT) prin-
ciple. To detect differences in the anthropometric measures as well
as dietary intakes between the two groups, we used an indepen-
dent samples Student’s t test. In addition, paired samples t test was
applied to detect a within-group difference. Pearson’s χ2 test was
used for the comparison of categorical variables. To determine the
effects of Se administration on markers of insulin metabolism, lipid
concentrations, biomarkers of inflammation and oxidative stress,
we used one-way repeated-measures ANOVA. To control
confounding variables (baseline values, age and BMI at the base-
line), we applied ANCOVA. P<0·05 was considered to be statis-
tically significant. All the statistical analyses were carried out using
the Statistical Package for Social Science version 18 (SPSS Inc.).
Results
Among patients in the Se group, three subjects were excluded.
Three subjects from the placebo group were also excluded.
Finally, fifty participants (Se (n 25) and placebo (n 25))
completed the trial (Fig. 1). Based on the ITT protocol, all fifty-six
patients (twenty-eight in each group) were included in the final
analysis. On average, the rate of compliance in our study was
high, such that >90 % of tablets were taken by the subjects
throughout the study in both the groups. Se supplementation in
CIN1 patients showed no side-effects throughout the study.
Mean age and height of the participants were not significantly
different between the Se supplement group and the placebo group.
Baseline weight and BMI as well as their means after 6 months of
the intervention were not significantly different between the two
groups (Table 1). Moreover, after 6 months of Se supplementation,
greater percentage of women in the Se group had regressed
CIN1 (88·0 v. 56·0%; P=0·01) compared with the placebo group.
Comparison of dietary intakes of the study participants
throughout the study revealed no significant differences in
macronutrient and micronutrient intakes, including energy,
carbohydrates, proteins, fats, SFA, PUFA, MUFA, cholesterol,
total dietary fibre, vitamin E, vitamin C, Mg, Mn and Se between
the two groups (data not shown).
Long-term Se supplementation, compared with the placebo,
resulted in significant decreases in FPG (−0·37 (SD 0·32) v. +0·07
(SD 0·63)mmol/l; P= 0·002), serum insulin levels (−28·8 (SD 31·2)
v. +13·2 (SD 40·2) pmol/l; P< 0·001), HOMA-IR (−1·3 (SD 1·3) v.
Randomised (n 56)
Allocated to placebo (n 28)
Lost to follow-up (n 3)
– Withdrawn (n 3)
Analysed (n 28)
Allocated to intervention (n 28)
Lost to follow-up (n 3)
– Withdrawn (n 3)
Analysed (n 28)
Assessed for eligibility (n 65)
Excluded (n 9)
– Not meeting inclusion criteria (n 9)
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Fig. 1. Summary of the patient flow diagram.
Table 1. General characteristics of the study participants
(Mean values and standard deviations)
Placebo group
(n 28)
Se group
(n 28)
Mean SD Mean SD P*
Age (years) 38·3 9·2 38·3 9·1 0·98
Height (cm) 158·5 6·3 159·6 6·3 0·52
Weight at study baseline (kg) 72·3 11·0 72·9 10·9 0·81
Weight at end-of-trial (kg) 71·9 10·7 73·1 10·6 0·65
Weight change (kg) −0·4 1·5 0·2 1·6 0·20
BMI at study baseline (kg/m2) 28·7 3·9 28·6 4·0 0·90
BMI at end-of-trial (kg/m2) 28·6 3·7 28·7 3·9 0·91
BMI change (kg/m2) −0·1 0·7 0·1 0·6 0·15
CIN1 regression (%) 14 56·0† 22 88·0† 0·01‡
CIN1, cervical intraepithelial neoplasia grade 1.
* Obtained from the independent t test.
† The analysis was carried out on twenty-five patients, three subjects were excluded.
‡ Obtained from Pearson’s χ2 test.
Selenium and cervical intraepithelial neoplasia 2041
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Table 2. Metabolic profiles, biomarkers of inflammation and oxidative stress at study baseline and after 6 months of intervention in women with cervical intraepithelial neoplasia grade 1 (CIN1) who received
either selenium supplements or placebo
(Mean values and standard deviations)
Placebo group (n 28) Se group (n 28)
Baseline End-of-trial Change Baseline End-of-trial Change
Mean SD Mean SD Mean SD P * Mean SD Mean SD Mean SD P * P†
FPG (mg/dl)‡ 89·4 8·3 90·7 11·8 1·3 11·6 0·58 94·5 12·1 87·7 9·7 −6·9 5·9 <0·001 0·002
Insulin (μIU/ml)§ 12·7 4·4 14·9 7·3 2·2 6·7 0·09 13·9 4·5 9·1 4·6 −4·8 5·2 <0·001 <0·001
HOMA-IR 2·8 1·0 3·3 1·5 0·5 1·4 0·09 3·3 1·4 2·0 1·0 −1·3 1·3 <0·001 <0·001
HOMA-B 48·1 18·2 57·9 33·4 9·8 30·7 0·10 48·9 14·0 34·0 19·5 −14·9 20·4 0·001 0·001
QUICKI 0·33 0·01 0·32 0·02 −0·01 0·01 0·21 0·32 0·02 0·35 0·04 0·03 0·03 <0·001 <0·001
TAG (mg/dl)|| 100·9 35·2 115·4 45·9 14·5 35·4 0·04 136·6 69·3 123·3 58·8 −13·3 50·0 0·17 0·02
VLDL-cholesterol (mg/dl)¶ 20·2 7·1 23·1 9·2 2·9 7·1 0·04 27·3 13·9 24·7 11·7 −2·6 10·0 0·17 0·02
Total cholesterol (mg/dl)¶ 174·3 26·1 173·4 24·6 −0·9 17·5 0·78 173·3 39·4 184·2 37·8 10·9 26·7 0·04 0·05
LDL-cholesterol (mg/dl)¶ 96·1 21·6 92·9 23·0 −3·2 15·2 0·28 91·7 31·6 99·8 30·7 8·1 26·3 0·11 0·05
HDL-cholesterol (mg/dl)¶ 58·1 9·6 57·4 8·3 −0·7 6·0 0·56 54·3 6·7 59·7 9·7 5·4 8·4 0·002 0·003
hs-CRP (ng/ml) 2631·2 3122·3 2441·2 2722·9 −190·0 2426·5 0·68 2589·9 1971·3 2667·8 2344·1 77·9 1688·2 0·80 0·63
NO (μmol/l) 52·0 7·5 57·0 13·2 5·0 13·6 0·06 40·5 13·4 52·6 7·3 12·1 13·4 <0·001 0·05
TAC (mmol/l) 826·5 141·9 869·3 185·4 42·8 180·4 0·22 798·9 155·5 985·0 301·5 186·1 274·6 0·001 0·02
GSH (μmol/l) 830·1 56·8 535·9 81·7 −294·2 581·8 0·01 824·9 336·5 889·9 198·3 65·0 359·8 0·34 0·007
MDA (μmol/l) 5·9 2·5 6·0 2·4 0·1 1·4 0·71 5·7 1·2 4·2 1·4 −1·5 2·1 0·001 0·001
FPG, fasting plasma glucose; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-B, homeostatic model assessment of β-cell function; QUICKI, quantitative insulin sensitivity check index; hs-CRP, high-sensitivity
C-reactive protein; NO, nitric oxide; TAC, total antioxidant capacity; MDA, malondialdehyde.
* Obtained from paired samples t test.
† Obtained from repeated-measures ANOVA test.
‡ To convert FBG in mg/dl to mmol/l, multiply by 0·0555.
§ To convert insulin in μIU/ml to pmol/l, multiply by 6·945.
|| To convert TAG in mg/dl to mmol/l, multiply by 0·0113.
¶ To convert VLDL-cholesterol, total cholesterol, LDL-cholesterol and HDL-cholesterol in mg/dl to mmol/l, multiply by 0·0259.
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+0·5 (SD 1·4); P< 0·001), HOMA-B (−14·9 (SD 20·4) v. +9·8
(SD 30·7); P< 0·001) as well as a significant elevation in QUICKI
score (+0·03 (SD 0·03) v. −0·01 (SD 0·01); P< 0·001) (Table 2). In
addition, patients who received Se supplements had significantly
decreased serum TAG levels (−0·14 (SD 0·55) v. +0·15 (SD 0·38)
mmol/l; P= 0·02) and VLDL-cholesterol levels (−2·6 (SD 10·0) v.
+2·9 (SD 7·1)mg/dl; P= 0·02) and had significantly increased
serum HDL-cholesterol levels (+0·13 (SD 0·21) v. −0·01 (SD 0·15)
mmol/l; P= 0·003). In addition, compared with the placebo
group, there were significant elevations in plasma TAC (+186·1
(SD 274·6) v. +42·8 (SD 180·4)mmol/l; P= 0·02) and GSH (+65·0
(SD 359·8) v. −294·2 (SD 581·8) μmol/l; P= 0·007) and a significant
decrease in MDA levels (−1·5 (SD 2·1) v. +0·1 (SD 1·4) μmol/l;
P= 0·001) among those who were supplemented with Se. We did
not observe any significant effect on other lipid profiles and
inflammatory markers following the administration of Se
supplement.
Baseline levels of TAG, VLDL-cholesterol and NO were
significantly different between the two groups. Therefore, we
adjusted the analyses for baseline values, age and BMI at
baseline (Table 3). After further adjustment, no significant
changes in our findings occurred except for the levels of TAG
(P= 0·23), VLDL-cholesterol (P= 0·23) and total cholesterol
(P= 0·04).
Discussion
In the present study, we evaluated the effects of long-term
Se administration on the regression and metabolic status of
patients with CIN1. Our study demonstrated for the first time
that administration of 200 μg Se/d for 6 months in patients
with CIN1 resulted in its higher regression, improved
homeostatic glucose parameters, decreased serum TAG and
VLDL-cholesterol levels, increased HDL-cholesterol levels and
decreased oxidative stress compared with the placebo group.
We also found that taking Se supplements daily for 6 months
among CIN1 women resulted in its regression. To the best of
our knowledge, the effects of Se administration in patients with
CIN have not been evaluated so far. In a study by Kim et al.(1), it
was observed that Se levels were significantly lower in patients
with CIN or cancer compared with controls. Although an
inverse association was found between Se levels and the results
of other types of cancer studies, it is suggested that Se has
protective effects(18). Administration of a mixture of antioxidant
supplements, including 50 mg Se, 60 mg vitamin C, 10 mg
vitamin E and 303mg vitamin A, significantly lowered levels of
apoptosis and lipid peroxides among cervical cancer patients
undergoing postoperative radiotherapy compared with patients
who did not receive supplements(19). Several epidemiological
studies have also shown the significant associations between Se
intake and decreased risk of breast(20) and prostate(21) cancers.
Previous studies have reported that the cancer-preventive
action of Se may be due to the antioxidant effects of
Se–cysteine–glutathione peroxidase (GSHPx)(22,23). Moreover,
Se may result in increased expression of selenoproteins, which
in turn may decrease the risk of various types of cancer(7).
We found that Se administration for 6 months in patients
with CIN led to significant reductions in FPG, serum insulin
concentrations, HOMA-IR, HOMA-B, TAG, VLDL-cholesterol con-
centrations as well as significant elevations in QUICKI score and
HDL-cholesterol concentrations compared with the placebo group,
but it did not affect other lipid concentrations. Our previous study
among PCOS women demonstrated that 200 μg/d Se supple-
mentation for 8 weeks had beneficial effects on markers of insulin
metabolism, TAG and VLDL-cholesterol concentrations, but did not
influence other lipid profiles(10). These findings were in agreement
with results obtained by Alizadeh et al.(24) who noted significant
decreases in serum insulin levels and HOMA-IR score following Se
administration among pre-menopausal women with central obesity
for 6 weeks. In another study, supplementation with 100 μg Se/d in
pregnant women from the first trimester of pregnancy until delivery
did not affect lipid profiles(25). Se intake may improve homeostatic
glucose parameters and TAG levels by regulating the expressions of
genes responsible for the synthesis of the enzymes involved in the
carbohydrate metabolism, increased uptake of the glucose by
tissues(26) and the inhibition of inflammatory cytokines including
TNF-α and IL-1(27). The lack of a significant effect of Se intake on
other lipid concentrations in the present study might be explained
by the distinct trial design, various dosages of Se supplementation
used and subjects of the study.
The current study revealed that Se intake for 6 months had no
significant effect on serum hs-CRP and plasma NO concentrations
among CIN1 women compared with the placebo group. Supporting
our study, 200 μg Se administration/d for 3 months did not influence
any significant effect on CRP levels among patients with chronic
kidney disease(28). Furthermore, no significant difference in hs-CRP
concentrations was observed following the administration of
200 μg/d Se among haemodialysis patients for 12 weeks(29).
However, in our previous study, Se supplementation among GDM
Table 3. Adjusted changes in metabolic variables between groups after
6 months of intervention in women with cervical intraepithelial neoplasia
grade 1 (CIN1) who received either selenium supplements or placebo
(Mean values with their standard errors)
Placebo group (n 28) Se group (n 28)
Mean SE Mean SE P *
FPG (mg/dl) 0·3 1·7 −5·9 1·7 0·01
Insulin (μIU/ml) 1·9 1·1 −4·5 1·1 <0·001
HOMA-IR 0·3 0·2 −1·2 0·2 <0·001
HOMA-B 9·7 4·9 −14·7 4·9 0·001
QUICKI −0·004 0·005 0·03 0·005 <0·001
TAG (mg/dl) 7·3 7·6 −6·2 7·6 0·23
VLDL-cholesterol (mg/dl) 1·5 1·5 −1·2 1·5 0·23
Total cholesterol (mg/dl) −0·8 3·8 10·6 3·8 0·04
LDL-cholesterol (mg/dl) −2·2 3·5 7·1 3·5 0·06
HDL-cholesterol (mg/dl) −0·1 1·3 4·8 1·3 0·01
hs-CRP (ng/ml) −185·7 363·6 73·6 363·6 0·61
NO (μmol/l) 9·7 2·2 7·5 2·2 0·49
TAC (mmol/l) 49·6 41·1 179·4 41·1 0·03
GSH (μmol/l) −291·4 29·2 62·2 29·2 <0·001
MDA (μmol/l) 0·1 0·3 −1·5 0·3 <0·001
FPG, fasting plasma glucose; HOMA-IR, homeostatic model assessment of insulin
resistance; HOMA-B, homeostasic model assessment of β-cell function; QUICKI,
quantitative insulin sensitivity check index; hs-CRP, high-sensitivity C-reactive
protein; NO, nitric oxide; TAC, total antioxidant capacity; MDA, malondialdehyde.
* Obtained from ANCOVA test. Values are adjusted for baseline values, age and
baseline BMI.
Selenium and cervical intraepithelial neoplasia 2043
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women for 6 weeks resulted in a significant decrease in hs-CRP
levels(11). The baseline characteristics of the study patients as well
as the dosage of Se supplements along with the study duration
might result in some explanations for the different findings.
We found that taking Se supplements for 6 months was
associated with significant rises in plasma TAC, GSH con-
centrations and a significant decrease in MDA concentrations in
women with CIN compared with the placebo group. In
agreement with our study, the erythrocyte and plasma total
antioxidant status (TAS) and erythrocyte GSH levels had
significantly increased following the supplementation of Se
(twice daily with 0 1 mg doses) for 45 d in patients with epilepsy
and refractory epilepsy(30). In addition, 200 μg/d Se supple-
mentation among GDM patients for 6 weeks resulted in a
significant increase in plasma GSH and a significant decrease in
plasma MDA levels(11). However, other studies did not observe
such effects of Se administration on biomarkers of oxidative
stress. For instance, 200 μg/d Se supplementation for 3 weeks
did not influence TAS and GSH levels in normal weight and
overweight healthy subjects(31). Se administration may reduce
oxidative stress through participation along with selenoproteins
and in the GSHPx system(32) and by inhibiting the production of
reactive oxygen species/reactive N species(33).
To interpret our findings, some limitations need to be con-
sidered. We did not to evaluate the effects of Se administration
on HPV. Unfortunately, due to limited funding, we did not
examine the effects of Se supplementation on serum or urine Se
concentrations, Se-dependent antioxidant enzymes including
glutathione peroxidase isoforms, thioredoxin reductase and the
signalling pathway involved in CIN.
In conclusion, taking Se supplements for 6 months by women
with CIN1 led to its regression and had beneficial effects on the
markers of insulin metabolism, TAG, VLDL and HDL-cholesterol
concentrations as well as biomarkers of oxidative stress.
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